Combatting Febrile Neutropenia During Chemotherapy Cycles Facing the challenges of chemotherapy? Neulastim is here to help!
Neulastim Onpro
When chemotherapy-induced febrile neutropenia threatens your health, Neulastim provides the essential support you need. This treatment significantly reduces the risk of febrile neutropenia in adult patients undergoing cytotoxic chemotherapy for various malignancies, excluding chronic myeloid leukemia and myelodysplastic syndromes.
For optimal results, a single 6 mg dose (one pre-filled syringe) of Neulastim is recommended for each chemotherapy cycle, administered at least 24 hours after cytotoxic chemotherapy. This precise timing ensures maximum protection and improves overall health outcomes.
By choosing Neulastim, you are opting for a reliable and effective way to manage the risk of febrile neutropenia, helping you stay healthier and more resilient throughout your chemotherapy journey.
























